SCHEMBL13145702

SCHEMBL13145702

CN(c1ccc(Cl)c(C(C)(C)C)c1)S(C)(=O)=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.40
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
LMNA P02545 2/20 0.40
USP2 O75604 1/20 0.40
HTT P42858 5/20 0.40
ALDH1A1 P00352 3/20 0.40
RAB9A P51151 2/20 0.40
MAPK1 P28482 1/20 0.40
NR1H4 Q96RI1 1/20 0.39
KDM4E B2RXH2 2/20 0.39
PTGDR2 Q9Y5Y4 2/20 0.38
PKM P14618 1/20 0.37
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
RECQL P46063 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
NPC1 O15118 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12018096 0.80 MAPT (0.48) MAPTMEN1KMT2ALMNAUSP2
SCHEMBL13145700 0.78 USP2 (0.47) MEN1KMT2ALMNAUSP2HTT
SCHEMBL11367059 0.77 KDM4E (0.42) MAPTMEN1KMT2ALMNAUSP2
SCHEMBL9464374 0.72 MAPT (0.42) MAPTMEN1KMT2ALMNAUSP2
SCHEMBL26511331 0.71 MAPT (0.39) MAPTMEN1KMT2ALMNAUSP2
SCHEMBL12457426 0.71 ALDH1A1 (0.52) MEN1KMT2ALMNAUSP2HTT
SCHEMBL6320855 0.70 ALDH1A1 (0.53) MAPTMEN1KMT2ALMNAUSP2
SCHEMBL5527324 0.69 HSD11B1 (0.43) MAPTMEN1KMT2ALMNAALDH1A1
SCHEMBL13145697 0.69 HPGD (0.49) MAPTLMNAHTTALDH1A1MAPK1
SCHEMBL15935218 0.69 ALDH1A1 (0.58) MAPTMEN1KMT2ALMNAUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100234364-A1 CCR2 INHIBITORS AND METHODS OF USE THEREOF CHEMOCENTRYX, INC. 2010-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234364-A1 CCR2 INHIBITORS AND METHODS OF USE THEREOF CCR2, CCR9, CCR1 MAPT 4415/4885MEN1 4867/4885KMT2A 2576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.